These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 7899374)

  • 21. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].
    Lee YN; Jeong SW; Lim JH; Ryu YS; Jeon SR; Kim SK; Jang JY; Kim YS; Kim BS; Roh MO
    Korean J Hepatol; 2010 Jun; 16(2):187-91. PubMed ID: 20606504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of reversible diabetes mellitus after cessation of interferon-alpha therapy for chronic hepatitis C infection.
    Tasi TN; Hsieh CH
    N Z Med J; 2004 Dec; 117(1207):U1230. PubMed ID: 15608817
    [No Abstract]   [Full Text] [Related]  

  • 23. [Autoimmune hemolytic anemia presenting during treatment of chronic hepatitis C with interferon alpha].
    Rizzi R; Lucarella FP; Ruggieri GB; L'Abbate M
    Ann Ital Med Int; 2003; 18(2):107-10. PubMed ID: 12886829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Massive increase of insulin resistance in a patient with chronic hepatitis C after treatment with interferon.
    Chatterjee S
    J Assoc Physicians India; 2004 Jun; 52():514. PubMed ID: 15645973
    [No Abstract]   [Full Text] [Related]  

  • 25. Human recombinant interferon alpha-2a (r IFN alpha-2a) therapy suppresses hepatic triglyceride lipase, leading to severe hypertriglyceridemia in a diabetic patient.
    Yamagishi S; Abe T; Sawada T
    Am J Gastroenterol; 1994 Dec; 89(12):2280. PubMed ID: 7977268
    [No Abstract]   [Full Text] [Related]  

  • 26. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection.
    Panetta JD; Gilani N
    Aliment Pharmacol Ther; 2009 Sep; 30(6):597-602. PubMed ID: 19549263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.
    Radhakrishnan S; Upadhyay A; Mohan N; Dhar A; Walia HK; Zubaidi G
    Med Princ Pract; 2005; 14(4):281-3. PubMed ID: 15961942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection.
    Akay BN; Ekmekci P; Sanli H; Celik G; Bozdayi M
    J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):442-5. PubMed ID: 16643145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Autoimmune hemolytic anemia induced by alpha-interferon therapy in a case of IgG-kappa type multiple myeloma].
    Onoda K; Takai K; Sanada M; Aoki S; Watanabe T
    Rinsho Ketsueki; 1992 Jun; 33(6):844-6. PubMed ID: 1433929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interferon treatment in chronic HCV hepatitis and autoimmune hypothyroidism].
    Calvo Manuel E; Nieto Sánchez A; Espinos Pérez D
    An Med Interna; 2000 Mar; 17(3):164-5. PubMed ID: 10804649
    [No Abstract]   [Full Text] [Related]  

  • 31. [Autoimmune thrombocytopenic purpura after treatment of chronic viral hepatitis C with interferon].
    Maïga MY; Oberti F; Foussard C; Calès P
    Gastroenterol Clin Biol; 1995; 19(8-9):739-40. PubMed ID: 8522132
    [No Abstract]   [Full Text] [Related]  

  • 32. Oral use of interferon-alpha delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice.
    Tanaka-Kataoka M; Kunikata T; Takayama S; Iwaki K; Fujii M; Ohashi K; Ikeda M; Kurimoto M
    J Interferon Cytokine Res; 1999 Aug; 19(8):877-9. PubMed ID: 10476932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus and type 1 diabetes.
    Fallahi P; Di Domenicantonio A; Mazzi V; Santini F; Fabiani S; Sebastiani M; Zignego AL; Ferri C; Antonelli A
    Clin Ter; 2013; 164(5):e437-44. PubMed ID: 24217846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoimmune polyglandular syndrome type 2 induced by treatment with interferon alpha.
    Krysiak R; Boldys A; Okopien B
    Am J Med Sci; 2011 Jun; 341(6):504-7. PubMed ID: 21412133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoimmune response as a side effect of treatment with interferon-α in melanoma: does this have prognostic implications?
    Palacios-Álvarez I; Román-Curto C; Mir-Bonafé JM; Cañueto J; Usero-Bárcena T; Fernández-López E
    Int J Dermatol; 2015 Mar; 54(3):e91-3. PubMed ID: 25521221
    [No Abstract]   [Full Text] [Related]  

  • 36. [Autoimmune thyroid disease induced by interferon therapy].
    Murakami M; Kakizaki S; Takayama H; Takagi H; Mori M
    Nihon Rinsho; 1999 Aug; 57(8):1779-83. PubMed ID: 10483250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis.
    Georgetson MJ; Yarze JC; Lalos AT; Webster GF; Martin P
    Am J Gastroenterol; 1993 Oct; 88(10):1756-8. PubMed ID: 8213720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Appearance of anti-DNA antibodies after treatment with interferon in a patient with chronic type C viral hepatitis].
    Ballardini P; Cicognani I; Montanari E; Fabbri F; Ferrari R; Del Noce A
    Riv Eur Sci Med Farmacol; 1995; 17(4):131-2. PubMed ID: 8545566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ingested type I interferon: a potential treatment for autoimmunity.
    Brod SA
    J Interferon Cytokine Res; 2002 Dec; 22(12):1153-66. PubMed ID: 12581487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia.
    Arimura K; Arima N; Ohtsubo H; Matsushita K; Kukita T; Ayukawa T; Kuroki T; Tei C
    Acta Haematol; 2004; 112(4):217-8. PubMed ID: 15564735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.